Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICOPA1-TOL nicotinamide in OPA1 dominant optic atrophy
2023-506214-52-00Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of nicotinamide in dominant optic atrophy (DOA), sponsored by Centre Hospitalier Universitaire d'Angers. Primary endpoint: Safety: ophthalmological and/or neurological adverse events. Started Sep 2023; status: completed.
02
Drugs
nicotinamide
03
Conditions
dominant optic atrophy (DOA)
Beyond the preview
Go deeper on 2023-506214-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506214-52-00.